title: The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.
abstract: Neisseria meningitidis serogroup B is the main cause for meningococcal invasive disease in many parts of the world. Since 2013, a new multicomponent vaccine against meningococcal serogroup B (4CMenB) has been licensed in Europe, Australia, Canada, Chile, Uruguay, USA and Brazil with different immunization schedules. Clinical trials involving adults, adolescents, children and infants showed 4CMenB has a good immunogenicity and safety profile. Strain coverage estimates are similar to or better than other recently approved vaccines, ranging from 66% in Canada to 91% in Unites States. Some points still remain to be clarified such as the best immunization strategy, the effect of 4CMenB on carriage, the long-term persistence of protective bactericidal antibodies titers, long-term safety outcomes, the possible emergence of N. meningitidis escape mutants and the vaccine cost-effectiveness. In this review, we focus on the vaccine composition, clinical trials and suggested schedules, safety data, potential strain coverage and future challenges.
authors.affiliation: Department of Pediatrics, Children's Hospital V. Buzzi, Via Castelvetro 32, University of Milan, Milan, Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Mameli
authors.affiliation: Department of Pediatrics, Children's Hospital V. Buzzi, Via Castelvetro 32, University of Milan, Milan, Italy.
authors.forename: Erica
authors.initials: E
authors.lastname: Galli
authors.affiliation: Department of Pediatrics, Children's Hospital V. Buzzi, Via Castelvetro 32, University of Milan, Milan, Italy.
authors.forename: Cecilia
authors.initials: C
authors.lastname: Mantegazza
authors.affiliation: Department of Pediatrics, Children's Hospital V. Buzzi, Via Castelvetro 32, University of Milan, Milan, Italy.
authors.forename: Valentina
authors.initials: V
authors.lastname: Fabiano
authors.affiliation: Department of Pediatrics, Children's Hospital V. Buzzi, Via Castelvetro 32, University of Milan, Milan, Italy.
authors.forename: Gian Vincenzo
authors.initials: GV
authors.lastname: Zuccotti
mesh_terms: D000293:Adolescent; D000328:Adult; D000942:Antigens, Bacterial / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008585:Meningitis, Meningococcal / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000009:adverse effects / Q000191:economics* / Q000276:immunology*; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D014611:Vaccination; D055815:Young Adult
chemical_list: D000942:Antigens, Bacterial; D022401:Meningococcal Vaccines
keywords: 4CMenB; MATS; Neisseria meningitidis; immunogenicity; reactogenicity; reverse vaccinology; vaccine